GENPHARMASEC
LIMITED

Date: 25.07.2025

To,
BSE Limited
The Compliance Department of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 531592

Subject: Update on acquisition of 70% stake in Derren Healthcare Private Limited

Ref: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

This is in continuation to our intimation dated 19th September, 2023, wherein Genpharmasec Limited ("the Company") had made disclosures under Reg. 30 of the listing regulations, 2015 informing the execution of Share Purchase Agreement [SPA] and Share Subscription cum Shareholders Agreement [SSSA] in relation to acquire of 70% stake in Derren Healthcare Private Limited in a staged manner.

We would like to inform you that the Company has on 25th July, 2025 acquired the 70% stake in Derren Healthcare Private Limited. Pursuant to completion of acquisition of shares of the Target Company, the Target Company has become a subsidiary of the Company as per the Regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

We are enclosing herewith the information pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with Master Circular No SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 is enclosed as **Annexure-A.**

Kindly take the same on records for your perusal.

Thanking you,

Yours faithfully,

For and behalf of the Board of Director of,
Genpharmasec Limited

SOHAN CHATURVEDI Digitally signed by SOHAN CHATURVEDI Date: 2025.07.25 17:00:04 +05'30'

GENPHARMASEC LIMITED KANDIVALI (E) MUMBAI 400 101.

Mr. Sohan Chaturvedi
Whole time director & CFO
DIN- 09629728

Encl:- as above

104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Soc Ltd., Akurli Road, Kandivali (East), Mumbai 400101.
compliance@genpharmasec.com
info@genpharmasec.com
+91-86555 50242
www.genpharmasec.com
CIN : L24231MH1992PLC323914

GENPHARMASEC LIMITED

Annexure-A

Disclosure under Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024:

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	Name: Derren Healthcare Private Limited ("DHPL") Authorized Share Capital: ₹ 7,50,00,000/- (Rupees Seven crore Fifty Lakh only) Paid up Share Capital: ₹ 7,40,41,210/- (Rupees Seven Crore Forty Lakh Forty One Thousand Two Hundred Ten only) Turnover: 858.82 lacs (for the financial year ended 31st March, 2025)
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, the nature of Interest and details thereof and whether the same is done at "arm's length":	No, the promoter & group companies do not have any interest in the entity Acquired.
3.	Industry to which the entity being acquired belongs:	Pharmaceutical Formulations
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).	To expand the activities of Genpharmasec Limited and to make a foray in manufacturing of formulations.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
6.	Indicative time period for completion of the acquisition;	Completed
7.	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash Consideration - payment made through banking system.
8.	Cost of acquisition or the price at which the shares are acquired;	The acquisition is done at a purchase consideration of INR 34.15 crs.
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	70% equity shares acquired by Genpharmasec Limited.
10.	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	DHPL is a research-oriented company aiming at the development of high-quality pharmaceutical products both in the field of generics and innovative finished formulations. DHPL Contract Research Organization-CRO & CDMO provides multiple research services for Pharmaceutical and Generic Drug Industries for both Indian & International companies. DHPL was incorporated on 8th October 2018.

GENPHARMASEC
LIMITED

		Turnover of last three financial years: 2024-25: 858.82 lacs 2023-24: 627.69 lacs 2022-23: 70.24 lacs Country in which the acquired entity has presence: India

104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Soc Ltd., Akurli Road, Kandivali (East), Mumbai 400101.
compliance@genpharmasec.com
info@genpharmasec.com
+91-86555 50242
www.genpharmasec.com